Oxford Cannabinoid Technologies announces strategic partnership with Evotec
We are delighted to announce a new INDiGO agreement with Evotec, a leading drug development company, which means that the development of our first cannabinoid medicine to treat chronic pain will advance more quickly. Evotec’s INDiGO programme is an integrated drug development process for accelerating early drug candidates to clinical trial stage. INDiGO increases development speed and optimises the chances of successfully progressing drug candidates to the clinic. This is a hugely significant step on the path to drug development.
Dr Valentino Parravicini, our Chief Scientific Officer, goes into further detail below: